Improving Outcomes for Patients With Advanced Urothelial Carcinoma

At JADPRO Live 2019, Petros Grivas, MD, PhD, and Jeannette Hammond, PA-C, reviewed data regarding mechanistic activity, efficacy, and safety of approved and emerging therapies for advanced or metastatic urothelial carcinoma, the selection of appropriate lines of therapy, and strategies for managing...

Descripción completa

Detalles Bibliográficos
Autores principales: Grivas, Petros, Hammond, Jeannette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857332/
https://www.ncbi.nlm.nih.gov/pubmed/33598327
http://dx.doi.org/10.6004/jadpro.2020.11.3.14
Descripción
Sumario:At JADPRO Live 2019, Petros Grivas, MD, PhD, and Jeannette Hammond, PA-C, reviewed data regarding mechanistic activity, efficacy, and safety of approved and emerging therapies for advanced or metastatic urothelial carcinoma, the selection of appropriate lines of therapy, and strategies for managing adverse events.

Ejemplares similares